Filtered By:
Condition: Heart Attack
Education: Academia

This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 486 results found since Jan 2013.

Approaches in Prehospital Sepsis Screening
Discussion In the United States, sepsis is one of the leading causes of death, which requires timely identification and proper treatment (CDC, 2019; Guerra et al., 2020; Polito et al., 2015). Based upon a review of literature conducted from 2014 to 2018, the primary investigators could locate five prehospital EMS screening tools to assist EMS providers in identifying at-risk sepsis patients. The researchers explored how the modified SIRS and qSOFA scoring systems were used in hospital settings in addition to these five prehospital EMS screening tools. The Bas 90-30-90, Guerra, PRESEP, PRESS, and Robson tools have ove...
Source: JEMS Operations - January 5, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Exclusives Patient Care EMS EMT Paramedic Prehospital Sepsis Source Type: news

Application of the Modified High Bleeding Risk Criteria for Japanese Patients in an All-Comers Registry of Percutaneous Coronary Intervention 　- From the CREDO-Kyoto Registry Cohort-3.
CONCLUSIONS: The J-HBR criteria successfully identified those patients with very high bleeding risk after PCI, who represented 64% of patients in this all-comers registry. PMID: 33298644 [PubMed - as supplied by publisher]
Source: Circulation Journal - December 8, 2020 Category: Cardiology Authors: Natsuaki M, Morimoto T, Shiomi H, Ehara N, Taniguchi R, Tamura T, Tada T, Suwa S, Kaneda K, Watanabe H, Tazaki J, Watanabe S, Yamamoto E, Saito N, Fuki M, Takeda T, Eizawa H, Shinoda E, Mabuchi H, Shirotani M, Uegaito T, Matsuda M, Takahashi M, Inoko M, T Tags: Circ J Source Type: research

Ticagrelor or Prasugrel in Patients with ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Conclusions: In patients with STEMI undergoing primary PCI, there was no significant difference in the primary endpoint between prasugrel and ticagrelor. Ticagrelor was associated with a significant increase in the risk for recurrent myocardial infarction. Clinical Trial Registration: URL: https://www.clinicaltrials.gov; Unique identifier NCT01944800. PMID: 33115278 [PubMed - as supplied by publisher]
Source: Circulation - October 29, 2020 Category: Cardiology Authors: Aytekin A, Ndrepepa G, Neumann FJ, Menichelli M, Mayer K, Wöhrle J, Bernlochner I, Lahu S, Richardt G, Witzenbichler B, Sibbing D, Cassese S, Angiolillo DJ, Valina C, Kufner S, Liebetrau C, Hamm CW, Xhepa E, Hapfelmeier A, Sager HB, Wustrow I, Joner M, T Tags: Circulation Source Type: research

Hospital Volumes of 5 Medical Emergencies in the COVID-19 Pandemic in 2 US Medical Centers
This cohort study assesses the association of the COVID-19 pandemic with the incidence of 5 medical emergencies (acute myocardial infarction, ischemic stroke, nontraumatic subarachnoid hemorrhage, ectopic pregnancy, and appendicitis) in 2 US academic medical centers.
Source: JAMA Internal Medicine - October 26, 2020 Category: Internal Medicine Source Type: research

Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS
Conclusion  Among patients with or without NSTE-ACS who have completed an initial 3-month course of DAPT following PCI with DES, ticagrelor monotherapy reduced clinically meaningful bleeding events without increasing ischaemic risk as compared with ticagrelor plus aspirin. The benefits of ticagrelor monotherapy with respect to bleeding events were more pronounced in patients with NSTE-ACS.Trial registrationClinicaltrials.gov identifier: NCT02270242.
Source: European Heart Journal - October 20, 2020 Category: Cardiology Source Type: research

Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque.
Conclusions: Cardiovascular events were higher after initiation of ICIs, potentially mediated by accelerated progression of atherosclerosis. Optimization of cardiovascular risk factors and increased awareness of cardiovascular risk, prior to, during and after treatment, should be considered among patients on an ICI. PMID: 33003973 [PubMed - as supplied by publisher]
Source: Circulation - October 1, 2020 Category: Cardiology Authors: Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, Mosarla RC, Lee C, Zlotoff DA, Raghu VK, Hartmann SE, Gilman HK, Gong J, Zubiri L, Sullivan RJ, Reynolds KL, Mayrhofer T, Zhang L, Hoffmann U, Neilan TG Tags: Circulation Source Type: research

Discontinuing Aspirin After Short Term Use Versus Continuous Use with a P2Y12 Inhibitor for the Treatment of Patients with Type 2 Diabetes Mellitus Following Percutaneous Coronary Intervention: A Meta-analysis
ConclusionDiscontinuing ASA after short-term use for the treatment of patients with T2DM following PCI was not associated with any increased cardiovascular outcomes. Also, discontinuing ASA after short-term use and continuing the use of a P2Y12 inhibitor were somewhat safer in these patients with T2DM. Further research should follow.
Source: Diabetes Therapy - September 23, 2020 Category: Endocrinology Source Type: research

Relative impact of bleedings over ischaemic events in patients with heart failure: insights from the CARDIONOR registry
ConclusionsIn HF outpatients, antithrombotics are widely used. Bleeding occurs at a stable rate of 1.2% annually (as frequent as ischaemic events) and is associated with a dramatic increase in mortality (at least as severe as ischaemic events). Most events occurred in patients receiving anticoagulation. Knowledge of these findings may help physicians to manage antithrombotics in HF patients.
Source: ESC Heart Failure - September 10, 2020 Category: Cardiology Authors: Gilles Lemesle, Sandro Ninni, Pascal Groote, Guillaume Schurtz, Nicolas Lamblin, Christophe Bauters Tags: Original Research Article Source Type: research

Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials
ConclusionIn patients with ACS undergoing PCI, both prasugrel and ticagrelor were associated with similar cardiovascular outcomes and adverse bleeding events.
Source: Cardiovascular Drugs and Therapy - August 19, 2020 Category: Cardiology Source Type: research

Efficacy and Safety of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Myocardial Infarction: A Nationwide Cohort Study.
This study aimed to compare the efficacy and safety of ticagrelor versus clopidogrel in East Asian patients with AMI. Between July 2013 and December 2015, patients with AMI prescribed with dual antiplatelet therapy were identified from the National Health Insurance Research Database of Taiwan. Using propensity score weighting, ticagrelor was compared with clopidogrel for the primary efficacy endpoint (a composite of all-cause death, MI, and stroke) and bleeding. A total of 32,442 patients with AMI (ticagrelor: 10,057; clopidogrel: 22,385) were eligible for analysis. After propensity score weighting, ticagrelor was comparab...
Source: Clinical Pharmacology and Therapeutics - August 6, 2020 Category: Drugs & Pharmacology Authors: Chang CJ, Tung YC, Liu JR, Chang SH, Kuo CT, See LC Tags: Clin Pharmacol Ther Source Type: research

A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs. Ticagrelor in Stabilized Patients with Acute Myocardial Infarction after Percutan eous Coronary Intervention: rationale and design of the TALOS-AMI trial.
CONCLUSIONS: The TALOS-AMI trial is the first large-scale, multicenter, randomized study exploring the efficacy and safety of the de-escalating antiplatelet therapy that switches ticagrelor to clopidogrel in stabilized AMI patients undergoing PCI. PMID: 32718912 [PubMed - as supplied by publisher]
Source: EuroIntervention - July 30, 2020 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research

Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes: Results From a Randomized Trial.
CONCLUSION: In elderly or low-weight patients with ACS, a reduced dose of prasugrel compared with the standard dose of ticagrelor is associated with maintained anti-ischemic efficacy while protecting these patients against the excess risk for bleeding. PRIMARY FUNDING SOURCE: German Center for Cardiovascular Research and Deutsches Herzzentrum München. PMID: 32687741 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - July 20, 2020 Category: Internal Medicine Authors: Menichelli M, Neumann FJ, Ndrepepa G, Mayer K, Wöhrle J, Bernlochner I, Richardt G, Witzenbichler B, Sibbing D, Gewalt S, Angiolillo DJ, Lahu S, Hamm CW, Hapfelmeier A, Trenk D, Laugwitz KL, Schunkert H, Schüpke S, Kastrati A Tags: Ann Intern Med Source Type: research

Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial.
CONCLUSION: Ordinal outcomes can improve efficiency through required pre-specification, careful construction, and analyses. Greater pragmatism can be obtained by composing outcomes within patients. Desirability of outcome ranking provides a global assessment of the benefits and harms that more closely reflect the experience of patients. The desirability of outcome ranking probability, the proportion in favor of treatment, the win ratio, and partial credit can more optimally inform patient treatment, enhance the understanding of the totality of intervention effects on patients, and potentially provide efficiencies over stan...
Source: Clinical Trials - July 14, 2020 Category: Research Authors: Evans SR, Knutsson M, Amarenco P, Albers GW, Bath PM, Denison H, Ladenvall P, Jonasson J, Easton JD, Minematsu K, Molina CA, Wang Y, Wong KL, Johnston SC Tags: Clin Trials Source Type: research

Screening strategies for adults with type 2 diabetes mellitus: a systematic review protocol
DiscussionThe protocol outlines the methods for systematically reviewing and synthesising evidence of screening strategies for type 2 diabetes mellitus and their effect on health outcomes associated with the disease. The potential impact of this systematic review is improved evidence-informed decision-making for policies and practice for screening of type-2 diabetes.Systematic review registrationPROSPERO CRD42020147439
Source: Systematic Reviews - July 12, 2020 Category: International Medicine & Public Health Source Type: research